Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Cancer cells co-opt pain-sensing 'wasabi receptor' to survive oxidative stress
(Harvard Medical School) Some cancers express unusually high levels of a neural calcium channel known as the 'wasabi receptor,' which plays a role in detecting pain, cold and other sensations. New research finds cancer cells co-opt this neural channel to increase their tolerance against toxic oxidative stress. Blocking the activity of this channel in mice curbs tumor growth and makes cancer cells more sensitive to chemotherapy. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 24, 2018 Category: Cancer & Oncology Source Type: news

Secondary Surgery Associated With Improved Survival in Ovarian Cancer
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone. (Source: CancerNetwork)
Source: CancerNetwork - May 24, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Gynecologic Cancers SiteTerms/www.cannabissciencetech.com/News Ovarian Cancer Source Type: news

RenovoRx raises $7m for drug-device pancreatic cancer therapy
RenovoRx said today that it closed a $7 million tranche in a $10 million round to fund the development of its drug-device combination product designed to deliver chemotherapy directly to tumors in patients with locally advanced pancreatic cancer. The company’s round was led by Boston Scientific (NYSE:BSX) and joined by btov Partners, Astia Angels, Golden Seeds and others. Get the full story at our sister site, Drug Delivery Business News. The post RenovoRx raises $7m for drug-device pancreatic cancer therapy appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - May 23, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Funding Roundup Oncology Pharmaceuticals Regulatory/Compliance Vascular RenovoRx Source Type: news

Merck's Keytruda succeeds in late-stage lung cancer study
(Reuters) - Merck& Co on Wednesday said its cancer drug Keytruda helped extend survival and prevented disease progression when tested in a late-stage study in combination with chemotherapy for a type of lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - May 23, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

J & J ’ s Cerenovus wins FDA nod for Embotrap II revascularization device
Johnson & Johnson‘s (NYSE:JNJ) Cerenovus said today it won FDA 510(k) clearance for the Embotrap II revascularization device. The Irvine, Calif.-based J&J division said that the device is designed to quickly restore natural blood flow by retrieving emboli within the vasculature of the brain, using minimal compression to protect against further complications. Approval of the device came based on data from the Arise II study, in which investigators reported being able to restore blood flow in 80% of patients treated within three passes, and in approximately 50% within a single pass. More than 66% of p...
Source: Mass Device - May 21, 2018 Category: Medical Devices Authors: Fink Densford Tags: 510(k) Food & Drug Administration (FDA) Neurological Regulatory/Compliance Vascular cerenovus johnsonandjohnson Source Type: news

Experts Discuss Unique Side Effects of Immunotherapy
If you have mesothelioma and you’ve already received standard-of-care therapies, you may be considering an immunotherapy clinical trial. If you’re considering this option, a free immunotherapy teleconference is a great place to learn more. CancerCare recently hosted two one-hour education workshops featuring panels of immunotherapy experts. Part I of the teleconference presented an overview of immunotherapy. Part II of the teleconference, which is available online for free, focused exclusively on immunotherapy side effects. Understanding these issues and the role each patient plays in managing their own side ef...
Source: Asbestos and Mesothelioma News - May 21, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Comfort box gives Norfolk cancer patients a 'little lift'
The kindness in a box that is making a huge difference to women undergoing chemotherapy. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - May 19, 2018 Category: Consumer Health News Source Type: news

I Took the First FDA-Approved Migraine Prevention Treatment. It Transformed My Life
On Thursday, the Food and Drug Administration approved the first drug designed to prevent chronic migraine headaches. Aimovig, made by Amgen and Novartis, is a monthly, self-administered injection that blocks a molecule involved in migraine attacks. Over the course of three clinical trials, the drug was successful at reducing the frequency of migraines for chronic sufferers. It is expected to be available in as soon as a week and will cost $575 per month, though out-of-pocket costs will vary depending on insurance. This is the story of Susan Giordano, 58, whose chronic migraines have nearly ceased after taking a monthly s...
Source: TIME: Health - May 18, 2018 Category: Consumer Health News Authors: Susan Giordano Tags: Uncategorized healthytime medicine onetime Source Type: news

Doctor bought jet and Maserati from proceeds of unnecessary chemotherapy, authorities say
The business of chemotherapy treatment for arthritis has been good to Jorge Zamora-Quezada. The Texas doctor took to the air on his six-seat Eclipse 500 business jet, bought with some of the $50 million he was paid since 2000 administering a host of treatments to countless patients. And on land, Zamora-Quezada, 61, roared between various […]Related:NIH halts $100 million study of moderate drinking that is funded by alcohol industryExploding vape pen caused Florida man’s death, autopsy saysMen’s depression may lower chances for pregnancy in couples, NIH study suggests (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - May 17, 2018 Category: Consumer Health News Source Type: news

ONCOS-102 Mesothelioma Trial Moves Forward
Oncologists in Spain are recruiting patients for the randomized phase of the pleural mesothelioma clinical trial involving ONCOS-102, the promising immunotherapy vaccine. Optimism surrounding the trial stems from encouraging results obtained recently in the six-patient safety cohort used as a precautionary lead-in. The trial involves the vaccine in combination with standard-of-care chemotherapy for patients with inoperable disease. ONCOS-102 is a scientifically engineered adenovirus that is designed to activate a patient’s immune system to selectively target cancer cells. It is being developed by Targovax, a Scandina...
Source: Asbestos and Mesothelioma News - May 17, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - May 17, 2018 Category: Pharmaceuticals Source Type: news

Phase III IMpower150 study showed Roche ’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel
Roche today announced positive results from the Phase III IMpower150 study of Tecentriq ® (atezolizumab) and Avastin® (bevacizumab) plus carboplatin and paclitaxel (chemotherapy) for the initial (first-line) treatment of chemotherapy-naïve people with metastatic non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - May 17, 2018 Category: Pharmaceuticals Source Type: news

Improving survival in pancreatic cancer with platinum-based chemotherapy
(Johns Hopkins Medicine) A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than those without the mutations. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 17, 2018 Category: International Medicine & Public Health Source Type: news

Roche immunotherapy combination increases lung cancer survival - study
(Reuters) - Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim results of a late stage trial released on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Merck's Keytruda boosts response in hard-to-treat lung cancer
(Reuters) - The combination of Merck& Co's immunotherapy Keytruda and chemotherapy boosted response rates in patients with advanced hard-to-treat squamous cell lung cancer, the company said on Wednesday. (Source: Reuters: Health)
Source: Reuters: Health - May 16, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Duke Team Addresses Barriers to Oral Chemo
A streamlined nursing protocol reduced delays related to treatment with oral formulations of chemotherapy and immunotherapy, and increased patient satisfaction. (Source: CancerNetwork)
Source: CancerNetwork - May 16, 2018 Category: Cancer & Oncology Authors: Lori Smith, BSN, MSN, CRNP Tags: News Conferences/ONS Source Type: news

Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients? Yes or No to Chemo-IO Combo in High PD-L1 NSCLC Patients?
Thoracic oncologists Drs Jack West and Hossein Borghaei talk about when to add chemotherapy to immunotherapy in high PD-L1-expressing non-small cell lung cancer patients.Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 16, 2018 Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news

Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016
This research has led to a Practice Changing Update on DynaMed Plus. Itarticle concludes that CHOP plus 131 I tositumomab and CHOP plus rituximab may have similar 5- and 10-year overall survival, but CHOP plus rituximab may improve 10-year progression-free survival in adults with advanced follicular lymphoma. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 16, 2018 Category: Consumer Health News Source Type: news

Texas doctor accused of giving fake diagnoses, faces $240 million health care fraud case
A 70-year-old McAllen Texas resident, Maria Zapata, went to see Dr. Jorge Zamora-Quezada because one of her knees was bothering her. The rheumatologist told her she had arthritis and that he'd give her injections "to strengthen the cartilage" in her knee, she said. After years of treatment that didn't help, she went to another doctor who told her she didn't really have arthritis. Zapata was not the only patient to be misdiagnosed, according to a joint federal and local investigation. The task force investigating Zamora-Quezada announced Monday that he was being indicted in a $240 million medical fraud case. The D...
Source: CNN.com - Health - May 16, 2018 Category: Consumer Health News Source Type: news

Stunned scientists find BLUEBERRIES are better at destroying cancer cells than conventional radiation therapy alone
(Natural News) Cervical cancer strikes close to 13,000 women each year, claiming over 4,200 lives. Traditional treatment options include surgery to remove the affected tissue, radiation therapy using high energy x-rays to destroy cancer cells, chemotherapy drugs to destroy the affected cells (although healthy cells are killed too), or a combination thereof. However, these treatments... (Source: NaturalNews.com)
Source: NaturalNews.com - May 15, 2018 Category: Consumer Health News Source Type: news

FDA approves biosimilar drug for anemia treatment
The Food and Drug Administration on Tuesday approved Retacrit as a biosimilar to treat anemia caused by chronic kidney disease and chemotherapy. (Source: Health News - UPI.com)
Source: Health News - UPI.com - May 15, 2018 Category: Consumer Health News Source Type: news

FDA Approves Retacrit (epoetin alfa-epbx) as First Epoetin Alfa Biosimilar for the Treatment of Anemia
May 15, 2018 -- The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 15, 2018 Category: Drugs & Pharmacology Source Type: news

COUNTERPOINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer
Abiraterone has become the first-choice treatment for men with metastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Robert J. Jones, MBChB, PhD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate Cancer
Chemotherapy is the best option for the initial management of metastatic prostate cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 15, 2018 Category: Cancer & Oncology Authors: Mario A. Eisenberger, MD Pedro Isaacsson Velho, MD Tags: Genitourinary Cancers Oncology Journal Prostate Cancer Source Type: news

Study Evaluates Systemic Chemotherapy on Peritoneal Mesothelioma
Systemic chemotherapy, either before or after cytoreductive surgery, provided no improvement in long-term survival for patients with peritoneal mesothelioma, according to a recent study. The addition of systemic chemotherapy improved survival at the one-year mark, but there were no benefits at the two-, three- or five-year checkpoints. Systemic chemotherapy uses anti-cancer drugs that are injected into a vein or given by mouth. The median survival of surgical patients who received systemic chemotherapy did not improve, either. “We know surgery is the best option, and if the surgery is successful, chemotherapy may not...
Source: Asbestos and Mesothelioma News - May 15, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Cancer treatment: Dr Chris recommends this honey to help patients survive chemotherapy
CANCER treatment usually comes in the form of chemotherapy, but this can bring down a patient ’s white cell count - the cells of the immune system involved in protecting the body against both infectious disease and foreign invaders. Television doctor Dr Chris Steele recommended on This Morning a particular honey that could help keep chemotherapy patients' white cell count up. (Source: Daily Express - Health)
Source: Daily Express - Health - May 15, 2018 Category: Consumer Health News Source Type: news

FDA approves first epoetin alfa biosimilar for the treatment of anemia
The U.S. Food and Drug Administration today approved Retacrit (epoetin alfa-epbx) as a biosimilar to Epogen/Procrit (epoetin alfa) for the treatment of anemia caused by chronic kidney disease, chemotherapy, or use of zidovudine in patients with HIV infection. Retacrit is also approved for use before and after surgery to reduce the chance that red blood cell transfusions will be needed because of blood loss during surgery. (Source: World Pharma News)
Source: World Pharma News - May 15, 2018 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Chemo, radiation, therapy — and don't forget exercise
The prescription pad is increasingly getting a workout as exercise is being prescribed for a host of conditions, from depression to diabetes to cardiovascular disease. Now a group of Australian oncologists want to prescribe exercise for all cancer patients, alongside surgery, chemotherapy and radiation. (Source: CBC | Health)
Source: CBC | Health - May 15, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Axillary Ultrasound After Chemotherapy: Mayo Clinic Radio Health Minute
In this Mayo Clinic Radio Health Minute, Dr. Judy Boughey explains how breast cancer care is being tailored to a patients needs. To listen, click the link below. Axillary Ultrasound after Chemo (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - May 15, 2018 Category: Databases & Libraries Source Type: news

Former Nevada Sen. Harry Reid undergoes surgery for cancer
Former Nevada Sen. Harry Reid is recovering after undergoing surgery Monday to remove a cancerous tumor from his pancreas. The 78-year-old Reid will undergo chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - May 14, 2018 Category: Consumer Health News Source Type: news

Adjuvant Chemotherapy Key to Improving OS in Rectal Cancer
Retrospective study shows 30 patients need to be treated with adjuvant therapy to prevent a death at 3 years. (Source: CancerNetwork)
Source: CancerNetwork - May 14, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Colorectal Cancer News Source Type: news

Chemotherapy-induced peripheral neuropathy in long-term survivors of childhood cancer
(JAMA Network) A new study assesses chemotherapy-induced peripheral neuropathy in 121 long-term survivors of childhood cancer to detail clinical, functional, neurophysiological and patient-reported outcomes of the condition. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 14, 2018 Category: Cancer & Oncology Source Type: news

Panic over blood infection outbreaks in children's hospitals
All of the infections occurred in seriously ill children receiving intravenous medications through a catheter or central line, a device used to deliver medications such as chemotherapy. (Source: the Mail online | Health)
Source: the Mail online | Health - May 11, 2018 Category: Consumer Health News Source Type: news

Trial shows chemotherapy is helping kids live with pulmonary vein stenosis
(Boston Children's Hospital) A clinical trial shows that adding chemotherapy to a treatment regimen including catheterization and surgery can deter abnormal cellular growth and finally give children with pulmonary vein stenosis a chance to grow up.Results of the trial, run by the Boston Children's Hospital Pulmonary Vein Stenosis Program, were recently published in the Journal of Pediatrics. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 11, 2018 Category: International Medicine & Public Health Source Type: news

Scientist wants all Canadian kids with cancer to receive genetic test for drug reactions
A scientist who developed a lab test to predict whether children with cancer are susceptible to potentially life-threatening side effects from three chemotherapy drugs is now focusing on five other medications so parents and doctors can discuss safer, personalized treatment. (Source: CBC | Health)
Source: CBC | Health - May 10, 2018 Category: Consumer Health News Tags: News/Health Source Type: news

Older Couples Are Increasingly Living Apart. Here ’s Why
Three years ago, William Mamel climbed a ladder in Margaret Sheroff’s apartment and fixed a malfunctioning ceiling fan. “I love that you did this,” Sheroff exclaimed as he clambered back down. Spontaneously, Mamel drew Sheroff to him and gave her a kiss. “I kind of surprised her. But she was open to it,” he remembered. Since then, Mamel, 87, and Sheroff, 74, have become a deeply committed couple. “Most nights, I’ll have dinner with Marg and many nights I stay with her overnight,” Mamel explained. And yet, despite the romance, these North Carolina seniors live in separate hous...
Source: TIME: Health - May 10, 2018 Category: Consumer Health News Authors: Judith Graham / Kaiser Health News Tags: Uncategorized healthytime Sex/Relationships Source Type: news

Peritoneal Mesothelioma Specialist Takes Expertise to South Florida
Dr. Shanel Bhagwandin saw the steady flow of patients who traveled from Southeast Florida to New York’s renowned Mount Sinai Hospital for the specialized treatment of peritoneal mesothelioma cancer. He knew there was a better way, and he just made it happen. Bhagwandin made the 1,200-mile move himself — from Mount Sinai to the Jupiter Medical Center — to start the latest surgical oncology program that specializes in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). “This procedure can make a tremendous difference,” Bhagwandin told Asbestos.com. “And it makes a ...
Source: Asbestos and Mesothelioma News - May 10, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Osimertinib Improves Patient-Reported Outcomes in Advanced NSCLC
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non –small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - May 10, 2018 Category: Cancer & Oncology Authors: Dave Levitan Tags: Lung Cancer SiteTerms/www.cannabissciencetech.com/News Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Media News)
Source: Roche Media News - May 10, 2018 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Investor Update)
Source: Roche Investor Update - May 10, 2018 Category: Pharmaceuticals Source Type: news

Roche provides update on Phase III study of Tecentriq (atezolizumab) and Cotellic (cobimetinib) in people with heavily pre-treated locally advanced or metastatic colorectal cancer
Roche today announced that the Phase III IMblaze370 study evaluating the combination of Tecentriq ® (atezolizumab) and Cotellic® (cobimetinib) did not meet its primary endpoint of overall survival (OS) compared to regorafenib. The study evaluated the combination in people with difficult-to-treat, locally advanced or metastatic colorectal cancer (CRC) whose disease progressed or who were intole rant to at least two systemic chemotherapy regimens. (Source: Roche Media News)
Source: Roche Media News - May 10, 2018 Category: Pharmaceuticals Source Type: news

Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
This research article has led to a Practice Update in DynaMed Plus. It concludes that addition of pembrolizumab to chemotherapy with pemetrexed and platinum-based drug increases overall survival in patients with previously untreated metastatic nonsquamous non-small cell lung cancer. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 9, 2018 Category: Consumer Health News Source Type: news

Systemic treatments for metastatic cutaneous melanoma
This Systematic Review found high-quality evidence that many treatments offer better efficacy than chemotherapy, especially recently implemented treatments, such as small-molecule targeted drugs, which are used to treat melanoma with specific gene mutations. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 9, 2018 Category: Consumer Health News Source Type: news

Medical News Today: Scientists may have found 'best time' to administer chemo drugs
A genome-wide map of busiest DNA repair times could reduce chemotherapy damage to healthy tissue through optimum 24-hour timing of dosage, say researchers. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 9, 2018 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Hospitals in US sound alarm on impending chemotherapy shortages
Drugmakers in spotlight over whether they are doing enough to maintain supplies. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - May 9, 2018 Category: Biotechnology Authors: David Crow in New York Source Type: news

Hospitals in US sound alarm on impending chemotherapy shortages
Drugmakers in spotlight over whether they are doing enough to maintain supplies. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - May 9, 2018 Category: Health Management Authors: David Crow in New York Source Type: news

Hospitals in US sound alarm on impending chemotherapy shortages
Doctors say it would be ‘national tragedy’ if patients denied life-extending drugs (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 9, 2018 Category: Pharmaceuticals Source Type: news

Simple Post-Surgery Step Reduces Bladder Cancer Recurrence
Flushing the bladder with a common chemotherapy drug immediately after surgery significantly reduces the chances of bladder cancer returning, according to a major study led by Edward M. Messing, M.D., and an international clinical trials network funded by the National Cancer Institute. (Source: University of Rochester Medical Center Press Releases)
Source: University of Rochester Medical Center Press Releases - May 9, 2018 Category: Universities & Medical Training Authors: University of Rochester Medical Center Source Type: news

Daiichi Sankyo Announces Single Agent Quizartinib Significantly Prolongs Overall Survival Compared with Chemotherapy in Patients with Relapsed/Refractory AML with FLT3-ITD Mutations (QuANTUM-R Study)
Quizartinib is the first FLT3 inhibitor to demonstrate improved overall survival compared with chemotherapy in patients with relapsed/refractory acute myeloid leukemia (AML) with FLT3-ITD mutations, a very aggressive form of the disease associated with poo... Biopharmaceuticals, Oncology Daiichi Sankyo Company, quizartinib, acute myeloid leukemia, FLT3 inhibitor (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 8, 2018 Category: Pharmaceuticals Source Type: news